Biogen Inc. (Nasdaq: BIIB) has announced the initiation of three pivotal Phase 3 clinical studies for its investigational drug, felzartamab, targeting rare kidney diseases. These studies, set to commence in 2025, aim to explore the potential of felzartamab, an anti-CD38 monoclonal antibody, in treating a range of immune-mediated diseases. The first readouts from these studies are expected in 2027. The announcement was made during a virtual investor seminar, where Biogen highlighted its strategic expansion into immunology and rare diseases following the acquisition of Human Immunology Biosciences in 2024. Results from these studies will be presented in the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief on June 11, 2025, and is solely responsible for the information contained therein.